Leidos (LDOS) 10-Q 3 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Apr. 01, 2022	Apr. 26, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Apr. 1, 2022
Document Transition Report	false
Entity File Number	001-33072
Entity Registrant Name	Leidos Holdings, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-3562868
Entity Address, Address Line One	1750 Presidents Street,
Entity Address, City or Town	Reston,
Entity Address, State or Province	VA
Entity Address, Postal Zip Code	20190
City Area Code	571
Local Phone Number	526-6000
Title of 12(b) Security	Common stock, par value $.0001 per share
Trading Symbol	LDOS
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		136,662,094
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001336920
Current Fiscal Year End Date	--12-30

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions	Apr. 01, 2022	Dec. 31, 2021
Assets:
Cash and cash equivalents	$ 297	$ 727
Receivables, net	2,419	2,189
Inventory, net	279	274
Other current assets	492	429
Total current assets	3,487	3,619
Property, plant and equipment, net	674	670
Intangible assets, net	1,109	1,177
Goodwill	6,742	6,744
Operating lease right-of-use assets, net	600	612
Other assets	418	439
Total assets	13,030	13,261
Liabilities:
Accounts payable and accrued liabilities	2,214	2,141
Accrued payroll and employee benefits	724	605
Short-term debt and current portion of long-term debt	556	483
Total current liabilities	3,494	3,229
Long-term debt, net of current portion	4,569	4,593
Operating lease liabilities	582	589
Deferred tax liabilities	182	239
Other long-term liabilities	195	267
Total liabilities	9,022	8,917
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.0001 par value, 500 million shares authorized, 137 million and 140 million shares issued and outstanding at April 1, 2022, and December 31, 2021, respectively	0	0
Additional paid-in capital	1,928	2,423
Retained earnings	2,007	1,880
Accumulated other comprehensive income (loss)	20	(12)
Total Leidos stockholders’ equity	3,955	4,291
Non-controlling interest	53	53
Total stockholders' equity	4,008	4,344
Total liabilities and stockholders' equity	$ 13,030	$ 13,261

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Apr. 01, 2022	Dec. 31, 2021
Stockholders’ equity:
Common stock, par value (dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	137,000,000	140,000,000
Common stock, shares outstanding (in shares)	137,000,000	140,000,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2022	Apr. 02, 2021
Income Statement [Abstract]
Revenues	$ 3,494	$ 3,315
Cost of revenues	2,982	2,848
Selling, general and administrative expenses	236	159
Acquisition, integration and restructuring costs	3	5
Equity loss (earnings) of non-consolidated subsidiaries	2	(5)
Operating income	271	308
Non-operating expense:
Interest expense, net	(48)	(45)
Other expense, net	(1)	(1)
Income before income taxes	222	262
Income tax expense	(45)	(57)
Net income	177	205
Less: net income attributable to non-controlling interest	2	0
Net income attributable to Leidos common stockholders	$ 175	$ 205
Earnings per share:
Basic (dollars per share)	$ 1.26	$ 1.44
Diluted (dollars per share)	$ 1.25	$ 1.42

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2022	Apr. 02, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 177	$ 205
Foreign currency translation adjustments	2	(4)
Unrecognized gain on derivative instruments	29	13
Pension adjustments	1	0
Total other comprehensive income, net of taxes	32	9
Comprehensive income	209	214
Less: net income attributable to non-controlling interest	2	0
Comprehensive income attributable to Leidos common stockholders	$ 207	$ 214

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) - USD ($) shares in Millions, $ in Millions	Total	Leidos Holdings, Inc. stockholders' equity	Shares of common stock	Additional paid-in capital	Retained earnings	Accumulated other comprehensive income	Non-controlling interest
Beginning balance (in shares) at Jan. 01, 2021			142
Beginning Balance at Jan. 01, 2021	$ 3,871	$ 3,862		$ 2,580	$ 1,328	$ (46)	$ 9
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	205	205			205
Other comprehensive income, net of taxes	9	9				9
Issuances of stock	14	14		14
Repurchases of stock and other (in shares)			(1)
Repurchases of stock and other	(123)	(123)		(123)
Dividends	(49)	(49)			(49)
Stock-based compensation	15	15		15
Capital distributions to non-controlling interests	38						38
Ending balance (in shares) at Apr. 02, 2021			141
Ending Balance at Apr. 02, 2021	3,980	3,933		2,486	1,484	(37)	47
Beginning balance (in shares) at Dec. 31, 2021			140
Beginning Balance at Dec. 31, 2021	4,344	4,291		2,423	1,880	(12)	53
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	177	175			175		2
Other comprehensive income, net of taxes	32	32				32
Issuances of stock (shares)			1
Issuances of stock	15	15		15
Repurchases of stock and other (in shares)			(4)
Repurchases of stock and other	(526)	(526)		(526)
Dividends	(48)	(48)			(48)
Stock-based compensation	16	16		16
Capital distributions to non-controlling interests	(2)						(2)
Ending balance (in shares) at Apr. 01, 2022			137
Ending Balance at Apr. 01, 2022	$ 4,008	$ 3,955		$ 1,928	$ 2,007	$ 20	$ 53

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) (Parenthetical) - $ / shares	3 Months Ended
	Apr. 01, 2022	Apr. 02, 2021
Statement of Stockholders' Equity [Abstract]
Dividends (dollars per share)	$ 0.36	$ 0.34

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2022	Apr. 02, 2021
Cash flows from operations:
Net income	$ 177	$ 205
Adjustments to reconcile net income to net cash provided by operations:
Depreciation and amortization	85	77
Stock-based compensation	16	15
Deferred income taxes	(61)	0
Other	4	(8)
Change in assets and liabilities, net of effects of acquisitions:
Receivables	(232)	(10)
Other current assets and other long-term assets	(28)	5
Accounts payable and accrued liabilities and other long-term liabilities	(60)	(148)
Accrued payroll and employee benefits	124	50
Income taxes receivable/payable	68	53
Net cash provided by operating activities	93	239
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired	(2)	(218)
Divestiture of a business	9	0
Payments for property, equipment and software	(28)	(26)
Net cash used in investing activities	(21)	(244)
Cash flows from financing activities:
Net proceeds from commercial paper	75	0
Payments of long-term debt	(27)	(26)
Dividend payments	(51)	(50)
Repurchases of stock and other	(526)	(123)
Net capital (distribution to) contributions from non-controlling interests	(2)	38
Proceeds from issuances of stock	12	13
Net cash used in financing activities	(519)	(148)
Net decrease in cash, cash equivalents and restricted cash	(447)	(153)
Cash, cash equivalents and restricted cash at beginning of period	875	687
Cash, cash equivalents and restricted cash at end of period	428	534
Less: restricted cash at end of period	131	157
Cash and cash equivalents at end of period	297	377
Supplementary cash flow information:
Cash paid for income taxes, net of refunds	8	8
Cash paid for interest	38	35
Property, plant and equipment additions	2	0
Finance lease obligations	$ 0	$ 45

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Apr. 01, 2022
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Note 1–Basis of Presentation and Summary of Significant Accounting Policies Nature of Operations and Basis of Presentation Leidos Holdings, Inc. ("Leidos"), a Delaware corporation, is a holding company whose direct 100%-owned subsidiary and principal operating company is Leidos, Inc. Leidos is a FORTUNE 500 ® technology, engineering, and science company that provides services and solutions in the defense, intelligence, civil and health markets, both domestically and internationally. Leidos' customers include the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security, the Federal Aviation Administration, the Department of Veterans Affairs and many other U.S. civilian, state and local government agencies, foreign government agencies and commercial businesses. Unless indicated otherwise, references to "we," "us" and "our" refer collectively to Leidos Holdings, Inc. and its consolidated subsidiaries. We operate in three reportable segments: Defense Solutions, Civil and Health. Additionally, we separately present the unallocable costs associated with corporate functions as Corporate. We have a controlling interest in Mission Support Alliance, LLC ("MSA"), a joint venture with Centerra Group, LLC. We also have a controlling interest in Hanford Mission Integration Solutions, LLC ("HMIS"), the legal entity for the follow-on contract to MSA's contract and a joint venture with Centerra Group, LLC and Parsons Government Services, Inc. The financial results for MSA and HMIS are consolidated into our unaudited condensed consolidated financial statements. The unaudited condensed consolidated financial statements also include the balances of all voting interest entities in which Leidos has a controlling voting interest ("subsidiaries") and a variable interest entity ("VIE") in which Leidos is the primary beneficiary. The consolidated balances of the VIE are not material to the unaudited condensed consolidated financial statements for the periods presented. Intercompany accounts and transactions between consolidated companies have been eliminated in consolidation. The accompanying unaudited condensed financial information has been prepared in accordance with the rules of the U.S. Securities and Exchange Commission and accounting principles generally accepted in the United States of America ("GAAP"). Certain disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. Management evaluates these estimates and assumptions on an ongoing basis, including those relating to estimated profitability of long-term contracts, indirect billing rates, allowances for doubtful accounts, inventories, right-of-use assets and lease liabilities, fair value and impairment of intangible assets and goodwill, income taxes, stock-based compensation expense and contingencies. These estimates have been prepared by management on the basis of the most current and best available information; however, actual results could differ materially from those estimates. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, which consist of normal recurring adjustments, necessary for a fair presentation thereof. The results reported in these unaudited condensed consolidated financial statements are not necessarily indicative of the results that may be expected for the entire year. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report on Form 10-K filed on February 15, 2022. Accounting Standards Updates ("ASU") Adopted ASU 2021-08, Business Combinations (Topic 805) In October 2021, the FASB issued ASU 2021-08, which amends how contract assets and liabilities acquired in a business combination are measured. Current guidance requires contract assets and liabilities to be measured at fair value in accordance with ASC 805, Business Combinations. The amendments in this Update remove the requirement to measure contract assets and liabilities at fair value and instead require that they be recognized in accordance with ASC 606, Revenue from Contracts with Customers. The amendments in this Update are effective for public business entities for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and must be applied prospectively. Early adoption is permitted. We adopted the requirements of ASU 2021-08 using the prospective method effective the first day of fiscal 2022. For business combinations occurring after adoption, we will measure contract assets and liabilities acquired in accordance with ASC 606. Accounting Standards Updates Issued But Not Yet Adopted ASU 2020-04 and ASU 2021-01, Reference Rate Reform (Topic 848) In March 2020, the FASB issued ASU 2020-04 which provides companies with optional expedients and exceptions to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. This update provides optional expedients for applying accounting guidance to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of the reference rate reform. The amendments in this update are effective for all entities as of March 2020 and can be adopted using a prospective approach no later than December 31, 2022. In January 2021, the FASB issued ASU 2021-01 which amends the scope of ASU 2020-04. The amendments in this update are elective and provide optional relief for entities with hedge accounting and contract modifications affected by the discounting transition through December 31, 2022. Under this relief, entities may continue to account for contract modifications as a continuation of the existing contract and the continuation of the hedge accounting arrangement. We are currently evaluating the impacts of reference rate reform. We currently use the one-month LIBOR for which the rate publication will cease in June 2023. Changes in Estimates on Contracts Changes in estimates related to contracts accounted for using the cost-to-cost method of accounting are recognized in the period in which such changes are made for the inception-to-date effect of the changes, with the exception of contracts acquired through a business combination, where the adjustment is made for the period commencing from the date of acquisition. Changes in estimates on contracts were as follows: Three Months Ended April 1, April 2, (in millions, except per share amounts) Favorable impact $ 41 $ 31 Unfavorable impact (26) (19) Net impact to income before income taxes $ 15 $ 12 Impact on diluted EPS attributable to Leidos common stockholders $ 0.08 $ 0.06 The impact on diluted earnings per share ("EPS") attributable to Leidos common stockholders is calculated using the statutory tax rate. Revenue Recognized from Prior Obligations Revenue recognized from performance obligations satisfied in previous periods was $14 million and $9 million for the three months ended April 1, 2022, and April 2, 2021, respectively. The changes primarily related to revisions of variable consideration including award and incentive fees, and revisions to estimates at completion resulting from changes in contract scope, mitigation of contract risks or true-ups of contract estimates at the end of contract performance. Cash and Cash Equivalents Our cash equivalents are primarily comprised of investments in several large institutional money market accounts, with original maturity of three months or less. At April 1, 2022, and December 31, 2021, $176 million and $138 million, respectively, of outstanding payments were included within "Cash and cash equivalents" and "Accounts payable and accrued liabilities" correspondingly on the condensed consolidated balance sheets. Restricted Cash We have restricted cash balances, primarily representing advances from customers that are restricted for use on certain expenditures related to that customer's contract and cash collected from the sale of accounts receivable but not yet remitted to the financial institution (see Note 9–Sale of Accounts Receivable). Restricted cash balances are included as "Other current assets" in the condensed consolidated balance sheets. Our restricted cash balances were $131 million and $148 million at April 1, 2022, and December 31, 2021, respectively.

Revenues from Contracts with Cu

Revenues from Contracts with Customers	3 Months Ended
	Apr. 01, 2022
Revenue from Contract with Customer [Abstract]
Revenues from Contracts with Customers	Note 2–Revenues from Contracts with Customers Remaining Performance Obligations Remaining performance obligations ("RPO") represent the expected value of exercised contracts, both funded and unfunded, less revenue recognized to date. Remaining performance obligations do not include unexercised option periods and future potential task orders expected to be awarded under indefinite delivery/indefinite quantity ("IDIQ") contracts, General Services Administration Schedule or other master agreement contract vehicles, with the exception of certain IDIQ contracts where task orders are not competitively awarded and separately priced but instead are used as a funding mechanism, and where there is a basis for estimating future revenues and funding on future anticipated task orders. As of April 1, 2022, we had $15.4 billion of RPO and expect to recognize approximately 55% and 73% over the next 12 months and 24 months, respectively, with the remainder to be recognized thereafter. Disaggregation of Revenues We disaggregate revenues by customer-type, contract-type and geographic location for each of our reportable segments. These categories represent how the nature, timing and uncertainty of revenues and cash flows are affected. Disaggregated revenues by customer-type were as follows: Three Months Ended April 1, 2022 Defense Solutions Civil Health Total (in millions) DoD and U.S. Intelligence Community $ 1,539 $ 20 $ 238 $ 1,797 Other government agencies (1) 222 613 385 1,220 Commercial and non-U.S. customers 287 147 27 461 Total $ 2,048 $ 780 $ 650 $ 3,478 Three Months Ended April 2, 2021 Defense Solutions Civil Health Total (in millions) DoD and U.S. Intelligence Community $ 1,407 $ 13 $ 158 $ 1,578 Other government agencies (1) 272 605 407 1,284 Commercial and non-U.S. customers 278 125 26 429 Total $ 1,957 $ 743 $ 591 $ 3,291 (1) Includes federal government agencies other than the DoD and U.S. Intelligence Community, as well as state and local government agencies. Disaggregated revenues by contract-type were as follows: Three Months Ended April 1, 2022 Defense Solutions Civil Health Total (in millions) Cost-reimbursement and fixed-price-incentive-fee $ 1,183 $ 408 $ 167 $ 1,758 Firm-fixed-price 618 255 417 1,290 Time-and-materials and fixed-price-level-of-effort 247 117 66 430 Total $ 2,048 $ 780 $ 650 $ 3,478 Three Months Ended April 2, 2021 Defense Solutions Civil Health Total (in millions) Cost-reimbursement and fixed-price-incentive-fee $ 1,163 $ 374 $ 99 $ 1,636 Firm-fixed-price 553 262 392 1,207 Time-and-materials and fixed-price-level-of-effort 241 107 100 448 Total $ 1,957 $ 743 $ 591 $ 3,291 Disaggregated revenues by geographic location were as follows: Three Months Ended April 1, 2022 Defense Solutions Civil Health Total (in millions) United States $ 1,810 $ 741 $ 650 $ 3,201 International 238 39 — 277 Total $ 2,048 $ 780 $ 650 $ 3,478 Three Months Ended April 2, 2021 Defense Solutions Civil Health Total (in millions) United States $ 1,713 $ 704 $ 591 $ 3,008 International 244 39 — 283 Total $ 1,957 $ 743 $ 591 $ 3,291 Revenues by customer-type, contract-type and geographic location exclude lease income of $16 million and $24 million for the three months ended April 1, 2022 and April 2, 2021, respectively. Contract Assets and Liabilities Performance obligations are satisfied either over time as work progresses or at a point in time. Firm-fixed-price contracts are typically billed to the customer using milestone payments while cost-reimbursable and time and materials contracts are typically billed to the customer on a monthly or bi-weekly basis as indicated by the negotiated billing terms and conditions of the contract. As a result, the timing of revenue recognition, customer billings and cash collections for each contract results in a net contract asset or liability at the end of each reporting period. Contract assets consist of unbilled receivables, which is the amount of revenue recognized that exceeds the amount billed to the customer, where right to payment is not solely subject to the passage of time. Unbilled receivables exclude amounts billable where the right to consideration is unconditional. Contract liabilities consist of deferred revenue, which represents cash advances received prior to performance for programs and billings in excess of revenue recognized. The components of contract assets and contract liabilities consisted of the following: Balance sheet line item April 1, December 31, (in millions) Contract assets - current: Unbilled receivables Receivables, net $ 1,078 $ 1,022 Contract liabilities - current: Deferred revenue (1) Accounts payable and accrued liabilities $ 382 $ 364 Contract liabilities - non-current: Deferred revenue (1) Other long-term liabilities $ 25 $ 24 (1) Certain contracts record revenue net of cost of revenues, and therefore, the respective deferred revenue balance will not fully convert to revenue. The increase in unbilled receivables was primarily due to revenue recognized on certain contracts partially offset by the timing of billings. Revenue recognized for the three months ended April 1, 2022, of $188 million was included as a contract liability at December 31, 2021. Revenue recognized for the three months ended April 2, 2021, of $144 million was included as a contract liability at January 1, 2021.

Acquisitions, Divestitures, Goo

Acquisitions, Divestitures, Goodwill and Intangible Assets	3 Months Ended
	Apr. 01, 2022
Business Combinations [Abstract]
Acquisitions, Divestitures, Goodwill and Intangible Assets	Note 3–Acquisitions, Divestitures, Goodwill and Intangible Assets Business Acquisitions On May 7, 2021 (the "Purchase Date"), we completed the acquisition of Gibbs & Cox for purchase consideration of approximately $375 million, net of $1 million of cash acquired. Gibbs & Cox is an independent engineering and design firm specializing in naval architecture, marine engineering, management support and engineering consulting. As of April 1, 2022, we had completed the determination of fair values of the acquired assets and liabilities assumed. The final goodwill recognized of $276 million represents intellectual capital and the acquired assembled workforce, neither of which qualify for recognition as a separate intangible asset. All of the goodwill recognized is tax deductible. The following table summarizes the fair value of intangible assets acquired at the Purchase Date and the related weighted average amortization period: Weighted average amortization period Fair value (in years) (in millions) Programs 12 $ 89 For the three months ended April 1, 2022, $27 million of revenues related to the Gibbs & Cox acquisition were recognized within the Defense Solutions reportable segmen t. On September 21, 2021, we completed an immaterial strategic business acquisition for preliminary purchase consideration of approximately $36 million. In connection with the transaction, we recognized an $8 million program intangible asset and preliminary goodwill of $25 million. Aviation & Missile Solutions LLC ("AMS") Divestiture On November 22, 2021, we signed a definitive agreement within our Defense Solutions segment to dispose of its AMS business in order to focus on leading-edge and technologically advanced services, solutions and products. The net sales price is $15 million, and the divestiture was completed on April 29, 2022. Goodwill The following table presents changes in the carrying amount of goodwill by reportable segment: Defense Solutions Civil Health Total (in millions) Goodwill at January 1, 2021 $ 3,300 $ 2,047 $ 966 $ 6,313 Acquisitions of businesses 425 5 — 430 Divestiture of a business (1) — — (1) Goodwill re-allocation (17) 17 — — Foreign currency translation adjustments (26) 28 — 2 Goodwill at December 31, 2021 $ 3,681 $ 2,097 $ 966 $ 6,744 Acquisition of a business 1 — — 1 Divestiture of a business (4) — — (4) Foreign currency translation adjustments 8 (7) — 1 Goodwill at April 1, 2022 $ 3,686 $ 2,090 $ 966 $ 6,742 As previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021, the estimated fair value of the Security Products reporting unit within the Civil reportable segment exceeded the carrying value by approximately 6% as of the most recent assessment date. In the event that there are significant unfavorable changes to the forecasted cash flows of the reporting unit (including if the impact of COVID-19 on passenger travel levels is more prolonged or severe than what is incorporated into our forecast), terminal growth rates or the cost of capital used in the fair value estimates, we may be required to record a material impairment of goodwill at a future date. During the three months ended April 1, 2022, and April 2, 2021, there were no impairments to goodwill. Intangible Assets Intangible assets, net consisted of the following: April 1, 2022 December 31, 2021 Gross carrying value Accumulated amortization Net carrying value Gross carrying value Accumulated amortization Net carrying value (in millions) Finite-lived intangible assets: Programs $ 1,701 $ (866) $ 835 $ 1,722 $ (830) $ 892 Software and technology 230 (127) 103 230 (121) 109 Customer relationships 91 (16) 75 97 (18) 79 Backlog 6 (6) — 38 (37) 1 Trade names 1 (1) — 1 (1) — Total finite-lived intangible assets 2,029 (1,016) 1,013 2,088 (1,007) 1,081 Indefinite-lived intangible assets: In-process research and development 92 — 92 92 — 92 Trade names 4 — 4 4 — 4 Total indefinite-lived intangible assets 96 — 96 96 — 96 Total intangible assets $ 2,125 $ (1,016) $ 1,109 $ 2,184 $ (1,007) $ 1,177 Amortization expense was $59 million and $55 million for the three months ended April 1, 2022 and April 2, 2021, respectively. Program intangible assets are amortized over their respective estimated useful lives in proportion to the pattern of economic benefit based on expected future discounted cash flows. Backlog and trade name intangible assets are amortized on a straight-line basis over their estimated useful lives. Customer relationships and software and technology intangible assets are amortized either on a straight-line basis over their estimated useful lives or over their respective estimated useful lives in proportion to the pattern of economic benefit based on expected future discounted cash flows, as deemed appropriate. The estimated annual amortization expense as of April 1, 2022, was as follows: Fiscal year ending (in millions) 2022 (remainder of year) $ 173 2023 203 2024 150 2025 120 2026 96 2027 and thereafter 271 $ 1,013

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Apr. 01, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4–Fair Value Measurements The accounting standard for fair value measurements establishes a three-level fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: observable inputs such as quoted prices in active markets (Level 1); inputs other than quoted prices in active markets that are observable, either directly or indirectly, or quoted prices that are not active (Level 2); and unobservable inputs in which there is little or no market data (e.g., discounted cash flow and other similar pricing models), which requires us to develop our own assumptions about the assumptions that market participants would use in pricing the asset or liability (Level 3). The financial instruments measured at fair value on a recurring basis primarily consisted of the following: April 1, 2022 December 31, 2021 Carrying value Fair value Carrying value Fair value (in millions) Financial liabilities: Derivatives $ 13 $ 13 $ 53 $ 53 As of April 1, 2022, our derivatives primarily consisted of the cash flow interest rate swaps on $1.0 billion of the variable rate senior unsecured term loan (see "Note 5–Derivative Instruments"). The fair value of the cash flow interest rate swaps is determined based on observed values for underlying interest rates on the LIBOR yield curve and the underlying interest rate (Level 2 inputs). The carrying amounts of our financial instruments, other than derivatives, which include cash equivalents, accounts receivable, accounts payable and accrued expenses, are reasonable estimates of their related fair values. As of April 1, 2022, and December 31, 2021, the fair value of debt was $5.1 billion and $5.4 billion, respectively, and the carrying amount was $5.1 billion and $5.1 billion, respectively (see "Note 6–Debt"). The fair value of long-term debt is determined based on current interest rates available for debt with terms and maturities similar to our existing debt arrangements (Level 2 inputs). On May 7, 2021, and January 14, 2021, non-financial instruments measured at fair value on a non-recurring basis were recorded in connection with the acquisitions of Gibbs & Cox and 1901 Group. The fair values of the assets acquired and liabilities assumed were determined using Level 3 inputs. As of April 1, 2022, we did not have any assets or liabilities measured at fair value on a non-recurring basis.

Derivative Instruments

Derivative Instruments	3 Months Ended
	Apr. 01, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	Note 5–Derivative Instruments We manage our risk to changes in interest rates through the use of derivative instruments. We do not hold derivative instruments for trading or speculative purposes. For variable rate borrowings, we use fixed interest rate swaps, effectively converting a portion of the variable interest rate payments to fixed interest rate payments. These swaps are designated as cash flow hedges. The fair value of the interest rate swaps was as follows: Liability derivatives Balance sheet line item April 1, December 31, (in millions) Cash flow interest rate swaps Other long-term liabilities $ 13 $ 53 The cash flows associated with the interest rate swaps are classified as operating activities in the condensed consolidated statements of cash flows. Cash Flow Hedges We have interest rate swap agreements to hedge the cash flows of $1.0 billion of the variable rate senior unsecured term loan (the "Variable Rate Loan"). These interest rate swap agreements have a maturity date of August 2025 and a fixed interest rate of 3.00%. The objective of these instruments is to reduce variability in the forecasted interest payments of the Variable Rate Loan, which are based on the LIBOR rate. Under the terms of the interest rate swap agreements, we will receive monthly variable interest payments based on the one-month LIBOR rate and will pay interest at a fixed rate. The interest rate swap transactions were accounted for as cash flow hedges. The gain/loss on the swaps is reported as a component of other comprehensive income (loss) and is reclassified into earnings when the interest payments on the underlying hedged items impact earnings. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective. The effect of the cash flow hedges on other comprehensive income (loss) and earnings for the periods presented was as follows: Three Months Ended April 1, April 2, (in millions) Total interest expense, net presented in the condensed consolidated statements of income in which the effects of cash flow hedges are recorded $ 48 $ 45 Amount recognized in other comprehensive income $ 32 $ 12 Amount reclassified from accumulated other comprehensive income (loss) to interest expense, net $ 6 $ 5 We expect to reclassify net losses of $15 million from accumulated other comprehensive income into earnings during the next 12 months.

Debt

Debt	3 Months Ended
	Apr. 01, 2022
Debt Disclosure [Abstract]
Debt	Note 6–Debt Our debt consisted of the following: Stated interest rate Effective interest rate April 1, 2022 (1) December 31, 2021 (1) (in millions) Short-term debt: Commercial paper 0.52%-1.13% Various $ 75 $ — Senior unsecured term loans: $380 million term loan, due May 2022 1.59% 1.69% 380 380 Total short-term debt $ 455 $ 380 Long-term debt: Senior unsecured term loans: $1,925 million term loan, due January 2025 1.84% 2.11% $ 1,275 $ 1,298 Senior unsecured notes: $500 million notes, due May 2023 2.95% 3.17% 499 498 $500 million notes, due May 2025 3.63% 3.76% 497 497 $750 million notes due May 2030 4.38% 4.50% 738 738 $1,000 million notes, due February 2031 2.30% 2.38% 990 990 $250 million notes, due July 2032 7.13% 7.43% 247 247 $300 million notes, due July 2033 5.50% 5.88% 158 158 $300 million notes, due December 2040 5.95% 6.03% 216 216 Notes payable and finance leases due on various dates through fiscal 2032 1.56%-4.18% Various 50 54 Total long-term debt 4,670 4,696 Less current portion (101) (103) Total long-term debt, net of current portion $ 4,569 $ 4,593 (1) The carrying amounts of the senior unsecured term loans and notes as of April 1, 2022, and December 31, 2021, include the remaining principal outstanding of $5,041 million and $5,065 million, respectively, less total unamortized debt discounts and deferred debt issuances costs of $41 million and $43 million, respectively. Term Loans and Revolving Credit Facility We have a Credit Agreement (the "Credit Agreement") with certain financial institutions, which provided for a senior unsecured term loan facility in an aggregate principal amount of $1.9 billion (the "Term Loan Facility") and a $750 million senior unsecured revolving facility (the "Revolving Facility" and, together with the Term Loan Facility, the "Credit Facilities"). The Credit Facilities will mature in January 2025. The Revolving Facility permits two additional one-year extensions subject to lender consent. Borrowings under the Credit Agreement bear interest at a rate determined, at our option, based on either an alternate base rate or a LIBOR rate plus, in each case, an applicable margin that varies depending on our credit rating. The applicable margin range for LIBOR-denominated borrowings is from 1.13% to 1.75%. Based on our current ratings, the applicable margin for LIBOR-denominated borrowings is 1.38%. The financial covenants in the Credit Agreement require that we maintain, as of the last day of each fiscal quarter, a ratio of adjusted consolidated total debt to consolidated EBITDA of not more than 3.75 to 1.00, subject to two increases to 4.50 to 1.00 following a material acquisition, and a ratio of EBITDA to consolidated interest expense of not less than 3.50 to 1.00. On May 7, 2021, we entered into a Credit Agreement (the "2021 Credit Agreement") with certain financial institutions, which provided for a senior unsecured term loan facility in an aggregate principal amount of $380 million with maturity 364 days after the 2021 Credit Agreement date. The proceeds were used to fund the acquisition of Gibbs & Cox. Borrowings under the 2021 Credit Agreement bear interest at a rate determined, at our option, based on either an alternate base rate plus 0.13% or a LIBOR rate plus 1.13%. The financial covenants in the 2021 Credit Agreement require that we maintain, as of the last day of each fiscal quarter, a ratio of adjusted consolidated total debt to consolidated EBITDA of not more than 3.75 to 1.00, subject to increases to 4.50 to 1.00 following a material acquisition, and a ratio of EBITDA to consolidated interest expense of not less than 3.50 to 1.00. Commercial Paper We have a commercial paper program in which the Company may issue short-term unsecured commercial paper notes ("Commercial Paper Notes") not to exceed $750 million. The proceeds will be used for general corporate purposes, including working capital, capital expenditures, acquisitions and share repurchases. The Commercial Paper Notes are issued in minimum denominations of $0.25 million and have maturities of up to 397 days from the date of issuance. The Commercial Paper Notes either bear a stated or floating interest rate, if interest bearing, or will be sold at a discount from the face amount. As of April 1, 2022, we had $75 million of Commercial Paper Notes outstanding. Principal Payments and Debt Issuance Costs We made principal payments on our long-term debt of $27 million and $26 million during the three months ended April 1, 2022, and April 2, 2021, respectively. This activity included required principal payments on our term loans of $24 million for both the three months ended April 1, 2022, and April 2, 2021. As of April 1, 2022, and December 31, 2021, there were no borrowings outstanding under the Revolving Facility. Amortization of debt discount and debt issuance costs was $3 million and $2 million for the three months ended April 1, 2022, and April 2, 2021, respectively. The Credit Facilities, the 2021 Credit Agreement, Commercial Paper Notes, senior unsecured term loans and notes are fully and unconditionally guaranteed and contain certain customary restrictive covenants, including among other things, restrictions on our ability to create liens and enter into sale and leaseback transactions under certain circumstances. We were in compliance with all covenants as of April 1, 2022.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	3 Months Ended
	Apr. 01, 2022
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	Note 7–Accumulated Other Comprehensive Income (Loss) Changes in the components of accumulated other comprehensive income (loss) were as follows: Foreign currency translation adjustments Unrecognized gain (loss) on derivative instruments Pension adjustments Total accumulated other comprehensive income (loss) (in millions) Balance at January 1, 2021 $ 30 $ (70) $ (6) $ (46) Other comprehensive income (loss) (3) 18 17 32 Taxes (5) (8) (4) (17) Reclassification from accumulated other comprehensive income (loss) — 19 — 19 Balance at December 31, 2021 22 (41) 7 (12) Other comprehensive income (loss) (2) 32 1 31 Taxes 4 (9) — (5) Reclassification from accumulated other comprehensive income (loss) — 6 — 6 Balance at April 1, 2022 $ 24 $ (12) $ 8 $ 20 Reclassifications from unrecognized loss on derivative instruments are recorded in "Interest expense, net" in the condensed consolidated statements of income.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Apr. 01, 2022
Earnings Per Share [Abstract]
Earnings Per Share	Note 8–Earnings Per Share The following table provides a reconciliation of the weighted average number of shares outstanding used to compute basic and diluted EPS for the periods presented: Three Months Ended April 1, April 2, (in millions) Basic weighted average number of shares outstanding 139 142 Dilutive common share equivalents—stock options and other stock awards 1 2 Diluted weighted average number of shares outstanding 140 144 Anti-dilutive stock-based awards are excluded from the weighted average number of shares outstanding used to compute diluted EPS. The total outstanding stock options and vesting stock awards that were anti-dilutive were 1 million for both the three months ended April 1, 2022, and April 2, 2021. On February 16, 2022, we entered into an Accelerated Share Repurchase ("ASR") agreement with a financial institution to repurchase shares of our outstanding common stock. We paid $500 million to the financial institution and received an initial delivery of 4.5 million shares at an average price of $88.72 per share. The purchase was recorded to "Additional paid-in capital" in the condensed consolidated balance sheets. All shares delivered were immediately retired. The specific number of shares that we will ultimately receive under the ASR agreement will be based on the volume-weighted-average-price during the period February 17, 2022, to May 16, 2022.

Sale of Accounts Receivable

Sale of Accounts Receivable	3 Months Ended
	Apr. 01, 2022
Receivables [Abstract]
Sale of Accounts Receivable	Note 9–Sale of Accounts Receivable We have entered into purchase agreements with a financial institution which provide us the election to sell accounts receivable at a discount. The receivables sold are typically collectable from our customers within 30 days of the sale date. During the three months ended April 1, 2022, and April 2, 2021, we sold $209 million and $465 million, respectively, of accounts receivable under the agreements and received proceeds of $209 million and $464 million, respectively, which were classified as operating activities in the condensed consolidated statements of cash flows. These transfers have been recognized as a sale, as the receivables have been legally isolated from Leidos, the financial institution has the right to pledge or exchange the assets received and we do not maintain effective control over the transferred accounts receivable. Our only continuing involvement with the transferred financial assets is as the collection and servicing agent. As a result, the accounts receivable balance on the condensed consolidated balance sheets is presented net of the transferred amounts. No servicing asset or liability was recognized for continued servicing of the sold receivables, as the servicing fee approximates fair value. The difference between the carrying amount of the receivables sold and the net cash received was recognized as a loss on sale and was recorded within "Selling, general and administrative expenses" on the condensed consolidated statements of income. Sold receivables activity for the periods presented was as follows: Three Months Ended April 1, April 2, (in millions) Sales of accounts receivable $ 209 $ 465 Cash collections on sold receivables remitted to financial institution (209) (371) Outstanding balance sold to financial institution — 94 Cash collected but not yet remitted to financial institution — (19) Sold receivables due from customers $ — $ 75

Business Segments

Business Segments	3 Months Ended
	Apr. 01, 2022
Segment Reporting [Abstract]
Business Segments	Note 10–Business Segments Our operations and reportable segments are organized around the customers and markets we serve. We define our reportable segments based on the way the chief operating decision maker ("CODM"), currently our Chairman and Chief Executive Officer, manages operations for the purposes of allocating resources and assessing performance. The segment information for the periods presented was as follows: Three Months Ended April 1, April 2, (in millions) Revenues: Defense Solutions $ 2,049 $ 1,958 Civil 795 766 Health 650 591 Total revenues $ 3,494 $ 3,315 Operating income (loss): Defense Solutions $ 133 $ 152 Civil 43 74 Health 118 102 Corporate (23) (20) Total operating income $ 271 $ 308 The income statement performance measures used to evaluate segment performance are revenues and operating income. As a result, "Interest expense, net," "Other expense, net" and "Income tax expense" as reported in the condensed consolidated statements of income are not allocated to our segments. Under U.S. Government Cost Accounting Standards, indirect costs including depreciation expense are collected in indirect cost pools, which are then collectively allocated to the reportable segments based on a representative causal or beneficial relationship of the costs in the pool to the costs in the base. As such, depreciation expense is not separately disclosed on the condensed consolidated statements of income.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Apr. 01, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 11–Commitments and Contingencies Contingencies VirnetX, Inc. ("VirnetX") On April 10, 2018, a jury trial concluded in an additional patent infringement case brought by VirnetX against Apple, referred to as the Apple II case, in which the jury returned a verdict against Apple for infringement and awarded VirnetX damages in the amount of over $502 million. On April 11, 2018, in a second phase of the Apple II trial, the jury found Apple's infringement to be willful. On August 30, 2018, the federal trial court in the Eastern District of Texas entered a final judgment and rulings on post-trial motions in the Apple II case. The court affirmed the jury’s verdict of over $502 million and granted VirnetX’s motions for supplemental damages, a sunset royalty and royalty rate of $1.20 per infringing device, along with pre-judgment and post-judgment interest and costs. The court denied VirnetX’s motions for enhanced damages, attorneys’ fees and an injunction. The court also denied Apple’s motions for judgment as a matter of law and for a new trial. An additional sum of over $93 million for costs and pre-judgment interest was subsequently agreed upon pursuant to a court order, bringing the total award to VirnetX in the Apple II case to over $595 million. Apple filed an appeal of the judgment in the Apple II case with the U.S. Court of Appeals for the Federal Circuit, and on November 22, 2019, the Federal Circuit affirmed in part, reversed in part and remanded the Apple II case back to the District Court. The Federal Circuit affirmed that Apple infringed two of the patents at issue in the case, and ruled that Apple is precluded from making certain patent invalidity arguments. However, the Federal Circuit reversed the judgment that Apple infringed two other patents at issue, vacated the prior damages awarded in the Apple II case, and remanded the Apple II case back to the District Court for further proceedings regarding damages. On April 23, 2020, the District Court ordered a new trial on damages in the Apple II case, which was delayed by the coronavirus pandemic and started on October 26, 2020. On October 30, 2020, the jury awarded VirnetX $503 million in damages and specified a royalty rate of $0.84 per infringing device. In January 2021, the District Court entered final judgment affirming the jury award and the parties separately agreed on additional costs and interest of over $75 million, subject to Apple's appeal. On February 4, 2021, Apple filed a notice of appeal with the U.S. Court of Appeals for the Federal Circuit in the Apple II case. Under our agreements with VirnetX, Leidos would receive 25% of the proceeds obtained by VirnetX after reduction for attorneys' fees and costs. However, the verdict in the Apple II case remains subject to the ongoing and potential future proceedings and appeals. In addition, the patents at issue in these cases are subject to U.S. Patent and Trademark Office post-grant inter partes review and/or reexamination proceedings and related appeals, which may result in all or part of these patents being invalidated or the claims of the patents being limited. Thus, no assurances can be given when or if we will receive any proceeds in connection with these jury awards. In addition, if Leidos receives any proceeds, we are required to pay a royalty to the customer who paid for the development of the technology. Government Investigations and Reviews We are routinely subject to investigations and reviews relating to compliance with various laws and regulations with respect to our role as a contractor to federal, state and local government customers and in connection with performing services in countries outside of the United States. Adverse findings could have a material effect on our business, financial position, results of operations and cash flows due to our reliance on government contracts. As of April 1, 2022, active indirect cost audits by the Defense Contract Audit Agency remain open for fiscal 2016 and subsequent fiscal years. Although we have recorded contract revenues based upon an estimate of costs that we believe will be approved upon final audit or review, we cannot predict the outcome of any ongoing or future audits or reviews and adjustments, and if future adjustments exceed estimates, our profitability may be adversely affected. As of April 1, 2022, we believe we have adequately reserved for potential adjustments from audits or reviews of contract costs. Through its internal processes, the Company discovered, in late 2021, activities by its employees, third party representatives and subcontractors, raising concerns related to a portion of our business that conducts international operations. The Company is conducting an internal investigation, overseen by an independent committee of the Board of Directors, with the assistance of external legal counsel, to determine whether the identified conduct may have violated the Company’s Code of Conduct and potentially applicable laws, including the U.S. Foreign Corrupt Practices Act ("FCPA"). The Company has voluntarily self-reported this investigation to the Department of Justice and the Securities and Exchange Commission and is cooperating with both agencies. Because the investigation is ongoing, the Company cannot anticipate the timing, outcome or possible impact of the investigation, although violations of the FCPA and other applicable laws may result in criminal and civil sanctions, including monetary penalties, and reputational damage. Commitments We have outstanding letters of credit of $51 million as of April 1, 2022, principally related to performance guarantees on contracts. We also have outstanding surety bonds with a notional amount of $100 million, principally related to performance and subcontractor payment bonds on contracts. The value of the surety bonds may vary due to changes in the underlying project status and/or contractual modifications. As of April 1, 2022, the future expirations of the outstanding letters of credit and surety bonds were as follows: Fiscal year ending (in millions) 2022 (remainder of year) $ 38 2023 11 2024 81 2025 5 2026 2 2027 and thereafter 14 $ 151

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Apr. 01, 2022
Accounting Policies [Abstract]
Consolidation	We have a controlling interest in Mission Support Alliance, LLC ("MSA"), a joint venture with Centerra Group, LLC. We also have a controlling interest in Hanford Mission Integration Solutions, LLC ("HMIS"), the legal entity for the follow-on contract to MSA's contract and a joint venture with Centerra Group, LLC and Parsons Government Services, Inc. The financial results for MSA and HMIS are consolidated into our unaudited condensed consolidated financial statements. The unaudited condensed consolidated financial statements also include the balances of all voting interest entities in which Leidos has a controlling voting interest ("subsidiaries") and a variable interest entity ("VIE") in which Leidos is the primary beneficiary. The consolidated balances of the VIE are not material to the unaudited condensed consolidated financial statements for the periods presented. Intercompany accounts and transactions between consolidated companies have been eliminated in consolidation.
Basis of Accounting	The accompanying unaudited condensed financial information has been prepared in accordance with the rules of the U.S. Securities and Exchange Commission and accounting principles generally accepted in the United States of America ("GAAP"). Certain disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules.
Estimates	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. Management evaluates these estimates and assumptions on an ongoing basis, including those relating to estimated profitability of long-term contracts, indirect billing rates, allowances for doubtful accounts, inventories, right-of-use assets and lease liabilities, fair value and impairment of intangible assets and goodwill, income taxes, stock-based compensation expense and contingencies. These estimates have been prepared by management on the basis of the most current and best available information; however, actual results could differ materially from those estimates.
Accounting Standards Updates ("ASU") Adopted and Updates Issued But Not Yet Adopted	Accounting Standards Updates ("ASU") Adopted ASU 2021-08, Business Combinations (Topic 805) In October 2021, the FASB issued ASU 2021-08, which amends how contract assets and liabilities acquired in a business combination are measured. Current guidance requires contract assets and liabilities to be measured at fair value in accordance with ASC 805, Business Combinations. The amendments in this Update remove the requirement to measure contract assets and liabilities at fair value and instead require that they be recognized in accordance with ASC 606, Revenue from Contracts with Customers. The amendments in this Update are effective for public business entities for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and must be applied prospectively. Early adoption is permitted. We adopted the requirements of ASU 2021-08 using the prospective method effective the first day of fiscal 2022. For business combinations occurring after adoption, we will measure contract assets and liabilities acquired in accordance with ASC 606. Accounting Standards Updates Issued But Not Yet Adopted ASU 2020-04 and ASU 2021-01, Reference Rate Reform (Topic 848) In March 2020, the FASB issued ASU 2020-04 which provides companies with optional expedients and exceptions to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. This update provides optional expedients for applying accounting guidance to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of the reference rate reform. The amendments in this update are effective for all entities as of March 2020 and can be adopted using a prospective approach no later than December 31, 2022. In January 2021, the FASB issued ASU 2021-01 which amends the scope of ASU 2020-04. The amendments in this update are elective and provide optional relief for entities with hedge accounting and contract modifications affected by the discounting transition through December 31, 2022. Under this relief, entities may continue to account for contract modifications as a continuation of the existing contract and the continuation of the hedge accounting arrangement. We are currently evaluating the impacts of reference rate reform. We currently use the one-month LIBOR for which the rate publication will cease in June 2023.
Changes in Estimates on Contracts	Changes in estimates related to contracts accounted for using the cost-to-cost method of accounting are recognized in the period in which such changes are made for the inception-to-date effect of the changes, with the exception of contracts acquired through a business combination, where the adjustment is made for the period commencing from the date of acquisition.The impact on diluted earnings per share ("EPS") attributable to Leidos common stockholders is calculated using the statutory tax rate.The changes primarily related to revisions of variable consideration including award and incentive fees, and revisions to estimates at completion resulting from changes in contract scope, mitigation of contract risks or true-ups of contract estimates at the end of contract performance.
Cash and Cash Equivalents	Our cash equivalents are primarily comprised of investments in several large institutional money market accounts, with original maturity of three months or less.outstanding payments were included within "Cash and cash equivalents" and "Accounts payable and accrued liabilities" correspondingly on the condensed consolidated balance sheets.
Restricted Cash	We have restricted cash balances, primarily representing advances from customers that are restricted for use on certain expenditures related to that customer's contract and cash collected from the sale of accounts receivable butnot yet remitted to the financial institution (see Note 9–Sale of Accounts Receivable). Restricted cash balances are included as "Other current assets" in the condensed consolidated balance sheets.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Apr. 01, 2022
Accounting Policies [Abstract]
Schedule of changes In estimates on contracts	Changes in estimates on contracts were as follows: Three Months Ended April 1, April 2, (in millions, except per share amounts) Favorable impact $ 41 $ 31 Unfavorable impact (26) (19) Net impact to income before income taxes $ 15 $ 12 Impact on diluted EPS attributable to Leidos common stockholders $ 0.08 $ 0.06

Revenues from Contracts with _2

Revenues from Contracts with Customers (Tables)	3 Months Ended
	Apr. 01, 2022
Revenue from Contract with Customer [Abstract]
Schedule of disaggregated revenues	Disaggregated revenues by customer-type were as follows: Three Months Ended April 1, 2022 Defense Solutions Civil Health Total (in millions) DoD and U.S. Intelligence Community $ 1,539 $ 20 $ 238 $ 1,797 Other government agencies (1) 222 613 385 1,220 Commercial and non-U.S. customers 287 147 27 461 Total $ 2,048 $ 780 $ 650 $ 3,478 Three Months Ended April 2, 2021 Defense Solutions Civil Health Total (in millions) DoD and U.S. Intelligence Community $ 1,407 $ 13 $ 158 $ 1,578 Other government agencies (1) 272 605 407 1,284 Commercial and non-U.S. customers 278 125 26 429 Total $ 1,957 $ 743 $ 591 $ 3,291 (1) Includes federal government agencies other than the DoD and U.S. Intelligence Community, as well as state and local government agencies. Disaggregated revenues by contract-type were as follows: Three Months Ended April 1, 2022 Defense Solutions Civil Health Total (in millions) Cost-reimbursement and fixed-price-incentive-fee $ 1,183 $ 408 $ 167 $ 1,758 Firm-fixed-price 618 255 417 1,290 Time-and-materials and fixed-price-level-of-effort 247 117 66 430 Total $ 2,048 $ 780 $ 650 $ 3,478 Three Months Ended April 2, 2021 Defense Solutions Civil Health Total (in millions) Cost-reimbursement and fixed-price-incentive-fee $ 1,163 $ 374 $ 99 $ 1,636 Firm-fixed-price 553 262 392 1,207 Time-and-materials and fixed-price-level-of-effort 241 107 100 448 Total $ 1,957 $ 743 $ 591 $ 3,291 Disaggregated revenues by geographic location were as follows: Three Months Ended April 1, 2022 Defense Solutions Civil Health Total (in millions) United States $ 1,810 $ 741 $ 650 $ 3,201 International 238 39 — 277 Total $ 2,048 $ 780 $ 650 $ 3,478 Three Months Ended April 2, 2021 Defense Solutions Civil Health Total (in millions) United States $ 1,713 $ 704 $ 591 $ 3,008 International 244 39 — 283 Total $ 1,957 $ 743 $ 591 $ 3,291
Components of contract assets and contract liabilities	The components of contract assets and contract liabilities consisted of the following: Balance sheet line item April 1, December 31, (in millions) Contract assets - current: Unbilled receivables Receivables, net $ 1,078 $ 1,022 Contract liabilities - current: Deferred revenue (1) Accounts payable and accrued liabilities $ 382 $ 364 Contract liabilities - non-current: Deferred revenue (1) Other long-term liabilities $ 25 $ 24 (1) Certain contracts record revenue net of cost of revenues, and therefore, the respective deferred revenue balance will not fully convert to revenue.

Acquisitions, Divestitures, G_2

Acquisitions, Divestitures, Goodwill and Intangible Assets (Tables)	3 Months Ended
	Apr. 01, 2022
Business Combinations [Abstract]
Schedule of preliminary fair values of intangible assets acquired and related weighted average amortization periods	The following table summarizes the fair value of intangible assets acquired at the Purchase Date and the related weighted average amortization period: Weighted average amortization period Fair value (in years) (in millions) Programs 12 $ 89
Schedule of carrying amount of goodwill by reportable segment	The following table presents changes in the carrying amount of goodwill by reportable segment: Defense Solutions Civil Health Total (in millions) Goodwill at January 1, 2021 $ 3,300 $ 2,047 $ 966 $ 6,313 Acquisitions of businesses 425 5 — 430 Divestiture of a business (1) — — (1) Goodwill re-allocation (17) 17 — — Foreign currency translation adjustments (26) 28 — 2 Goodwill at December 31, 2021 $ 3,681 $ 2,097 $ 966 $ 6,744 Acquisition of a business 1 — — 1 Divestiture of a business (4) — — (4) Foreign currency translation adjustments 8 (7) — 1 Goodwill at April 1, 2022 $ 3,686 $ 2,090 $ 966 $ 6,742
Schedule of intangible assets	Intangible assets, net consisted of the following: April 1, 2022 December 31, 2021 Gross carrying value Accumulated amortization Net carrying value Gross carrying value Accumulated amortization Net carrying value (in millions) Finite-lived intangible assets: Programs $ 1,701 $ (866) $ 835 $ 1,722 $ (830) $ 892 Software and technology 230 (127) 103 230 (121) 109 Customer relationships 91 (16) 75 97 (18) 79 Backlog 6 (6) — 38 (37) 1 Trade names 1 (1) — 1 (1) — Total finite-lived intangible assets 2,029 (1,016) 1,013 2,088 (1,007) 1,081 Indefinite-lived intangible assets: In-process research and development 92 — 92 92 — 92 Trade names 4 — 4 4 — 4 Total indefinite-lived intangible assets 96 — 96 96 — 96 Total intangible assets $ 2,125 $ (1,016) $ 1,109 $ 2,184 $ (1,007) $ 1,177
Schedule of estimated annual amortization expense	The estimated annual amortization expense as of April 1, 2022, was as follows: Fiscal year ending (in millions) 2022 (remainder of year) $ 173 2023 203 2024 150 2025 120 2026 96 2027 and thereafter 271 $ 1,013

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Apr. 01, 2022
Fair Value Disclosures [Abstract]
Schedule of financial assets measured on a recurring basis	The financial instruments measured at fair value on a recurring basis primarily consisted of the following: April 1, 2022 December 31, 2021 Carrying value Fair value Carrying value Fair value (in millions) Financial liabilities: Derivatives $ 13 $ 13 $ 53 $ 53

Derivative Instruments (Tables)

Derivative Instruments (Tables)	3 Months Ended
	Apr. 01, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of fair value of the company's interest rate swaps	The fair value of the interest rate swaps was as follows: Liability derivatives Balance sheet line item April 1, December 31, (in millions) Cash flow interest rate swaps Other long-term liabilities $ 13 $ 53
Schedule of effect of the company's cash flow hedges on other comprehensive income and earnings	The effect of the cash flow hedges on other comprehensive income (loss) and earnings for the periods presented was as follows: Three Months Ended April 1, April 2, (in millions) Total interest expense, net presented in the condensed consolidated statements of income in which the effects of cash flow hedges are recorded $ 48 $ 45 Amount recognized in other comprehensive income $ 32 $ 12 Amount reclassified from accumulated other comprehensive income (loss) to interest expense, net $ 6 $ 5

Debt (Tables)

Debt (Tables)	3 Months Ended
	Apr. 01, 2022
Debt Disclosure [Abstract]
Schedule of company's debt	Our debt consisted of the following: Stated interest rate Effective interest rate April 1, 2022 (1) December 31, 2021 (1) (in millions) Short-term debt: Commercial paper 0.52%-1.13% Various $ 75 $ — Senior unsecured term loans: $380 million term loan, due May 2022 1.59% 1.69% 380 380 Total short-term debt $ 455 $ 380 Long-term debt: Senior unsecured term loans: $1,925 million term loan, due January 2025 1.84% 2.11% $ 1,275 $ 1,298 Senior unsecured notes: $500 million notes, due May 2023 2.95% 3.17% 499 498 $500 million notes, due May 2025 3.63% 3.76% 497 497 $750 million notes due May 2030 4.38% 4.50% 738 738 $1,000 million notes, due February 2031 2.30% 2.38% 990 990 $250 million notes, due July 2032 7.13% 7.43% 247 247 $300 million notes, due July 2033 5.50% 5.88% 158 158 $300 million notes, due December 2040 5.95% 6.03% 216 216 Notes payable and finance leases due on various dates through fiscal 2032 1.56%-4.18% Various 50 54 Total long-term debt 4,670 4,696 Less current portion (101) (103) Total long-term debt, net of current portion $ 4,569 $ 4,593 (1) The carrying amounts of the senior unsecured term loans and notes as of April 1, 2022, and December 31, 2021, include the remaining principal outstanding of $5,041 million and $5,065 million, respectively, less total unamortized debt discounts and deferred debt issuances costs of $41 million and $43 million, respectively.

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	3 Months Ended
	Apr. 01, 2022
Equity [Abstract]
Schedule of changes in the components of accumulated other comprehensive (loss) income	Changes in the components of accumulated other comprehensive income (loss) were as follows: Foreign currency translation adjustments Unrecognized gain (loss) on derivative instruments Pension adjustments Total accumulated other comprehensive income (loss) (in millions) Balance at January 1, 2021 $ 30 $ (70) $ (6) $ (46) Other comprehensive income (loss) (3) 18 17 32 Taxes (5) (8) (4) (17) Reclassification from accumulated other comprehensive income (loss) — 19 — 19 Balance at December 31, 2021 22 (41) 7 (12) Other comprehensive income (loss) (2) 32 1 31 Taxes 4 (9) — (5) Reclassification from accumulated other comprehensive income (loss) — 6 — 6 Balance at April 1, 2022 $ 24 $ (12) $ 8 $ 20

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Apr. 01, 2022
Earnings Per Share [Abstract]
Reconciliation of the weighted average number of shares outstanding used to compute basic and diluted EPS	The following table provides a reconciliation of the weighted average number of shares outstanding used to compute basic and diluted EPS for the periods presented: Three Months Ended April 1, April 2, (in millions) Basic weighted average number of shares outstanding 139 142 Dilutive common share equivalents—stock options and other stock awards 1 2 Diluted weighted average number of shares outstanding 140 144

Sale of Accounts Receivable (Ta

Sale of Accounts Receivable (Tables)	3 Months Ended
	Apr. 01, 2022
Receivables [Abstract]
Accounts receivable sale activity	Sold receivables activity for the periods presented was as follows: Three Months Ended April 1, April 2, (in millions) Sales of accounts receivable $ 209 $ 465 Cash collections on sold receivables remitted to financial institution (209) (371) Outstanding balance sold to financial institution — 94 Cash collected but not yet remitted to financial institution — (19) Sold receivables due from customers $ — $ 75

Business Segments (Tables)

Business Segments (Tables)	3 Months Ended
	Apr. 01, 2022
Segment Reporting [Abstract]
Schedule of segment reporting information by segment	The segment information for the periods presented was as follows: Three Months Ended April 1, April 2, (in millions) Revenues: Defense Solutions $ 2,049 $ 1,958 Civil 795 766 Health 650 591 Total revenues $ 3,494 $ 3,315 Operating income (loss): Defense Solutions $ 133 $ 152 Civil 43 74 Health 118 102 Corporate (23) (20) Total operating income $ 271 $ 308

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	3 Months Ended
	Apr. 01, 2022
Commitments and Contingencies Disclosure [Abstract]
Guaranteed obligation, fiscal year maturity	As of April 1, 2022, the future expirations of the outstanding letters of credit and surety bonds were as follows: Fiscal year ending (in millions) 2022 (remainder of year) $ 38 2023 11 2024 81 2025 5 2026 2 2027 and thereafter 14 $ 151

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details) $ in Millions	3 Months Ended
	Apr. 01, 2022USD ($)segment	Apr. 02, 2021USD ($)	Dec. 31, 2021USD ($)
Significant Accounting Policies [Line Items]
Number of reportable segments | segment	3
Revenue recognized for performance obligation satisfied in the previous periods	$ 14	$ 9
Accounts payable and accrued liabilities	2,214		$ 2,141
Restricted cash balances	131		148
Cash and Cash Equivalents
Significant Accounting Policies [Line Items]
Accounts payable and accrued liabilities	$ 176		$ 138

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies (Changes in Estimates on Contracts) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Apr. 01, 2022	Apr. 02, 2021
Accounting Policies [Abstract]
Favorable impact	$ 41	$ 31
Unfavorable impact	(26)	(19)
Net impact to income before income taxes	$ 15	$ 12
Impact on diluted EPS attributable to Leidos common stockholders (dollars per share)	$ 0.08	$ 0.06

Revenues from Contracts with _3

Revenues from Contracts with Customers (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2022	Apr. 02, 2021
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Remaining performance obligations, which are expected to be recognized as revenue	$ 15,400
Revenue recognized under ASC 842	16	$ 24
Contract liability revenue recognized	$ 188	$ 144
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Remaining performance obligations, which are expected to be recognized as revenue, period (in months)	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01 | Performance Period One
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Remaining performance obligations, which are expected to be recognized as revenue (as percent)	55.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01 | Performance Period Two
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Remaining performance obligations, which are expected to be recognized as revenue (as percent)	73.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Remaining performance obligations, which are expected to be recognized as revenue, period (in months)	24 months

Revenues from Contracts with _4

Revenues from Contracts with Customers (Disaggregation of revenue) (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2022	Apr. 02, 2021
Disaggregation of Revenue [Line Items]
Revenues	$ 3,478	$ 3,291
United States
Disaggregation of Revenue [Line Items]
Revenues	3,201	3,008
International
Disaggregation of Revenue [Line Items]
Revenues	277	283
Cost-reimbursement and fixed-price-incentive-fee
Disaggregation of Revenue [Line Items]
Revenues	1,758	1,636
Firm-fixed-price
Disaggregation of Revenue [Line Items]
Revenues	1,290	1,207
Time-and-materials and fixed-price-level-of-effort
Disaggregation of Revenue [Line Items]
Revenues	430	448
DoD and U.S. Intelligence Community
Disaggregation of Revenue [Line Items]
Revenues	1,797	1,578
Other government agencies
Disaggregation of Revenue [Line Items]
Revenues	1,220	1,284
Commercial and non-U.S. customers
Disaggregation of Revenue [Line Items]
Revenues	461	429
Defense Solutions
Disaggregation of Revenue [Line Items]
Revenues	2,048	1,957
Defense Solutions | United States
Disaggregation of Revenue [Line Items]
Revenues	1,810	1,713
Defense Solutions | International
Disaggregation of Revenue [Line Items]
Revenues	238	244
Defense Solutions | Cost-reimbursement and fixed-price-incentive-fee
Disaggregation of Revenue [Line Items]
Revenues	1,183	1,163
Defense Solutions | Firm-fixed-price
Disaggregation of Revenue [Line Items]
Revenues	618	553
Defense Solutions | Time-and-materials and fixed-price-level-of-effort
Disaggregation of Revenue [Line Items]
Revenues	247	241
Defense Solutions | DoD and U.S. Intelligence Community
Disaggregation of Revenue [Line Items]
Revenues	1,539	1,407
Defense Solutions | Other government agencies
Disaggregation of Revenue [Line Items]
Revenues	222	272
Defense Solutions | Commercial and non-U.S. customers
Disaggregation of Revenue [Line Items]
Revenues	287	278
Civil
Disaggregation of Revenue [Line Items]
Revenues	780	743
Civil | United States
Disaggregation of Revenue [Line Items]
Revenues	741	704
Civil | International
Disaggregation of Revenue [Line Items]
Revenues	39	39
Civil | Cost-reimbursement and fixed-price-incentive-fee
Disaggregation of Revenue [Line Items]
Revenues	408	374
Civil | Firm-fixed-price
Disaggregation of Revenue [Line Items]
Revenues	255	262
Civil | Time-and-materials and fixed-price-level-of-effort
Disaggregation of Revenue [Line Items]
Revenues	117	107
Civil | DoD and U.S. Intelligence Community
Disaggregation of Revenue [Line Items]
Revenues	20	13
Civil | Other government agencies
Disaggregation of Revenue [Line Items]
Revenues	613	605
Civil | Commercial and non-U.S. customers
Disaggregation of Revenue [Line Items]
Revenues	147	125
Health
Disaggregation of Revenue [Line Items]
Revenues	650	591
Health | United States
Disaggregation of Revenue [Line Items]
Revenues	650	591
Health | International
Disaggregation of Revenue [Line Items]
Revenues	0	0
Health | Cost-reimbursement and fixed-price-incentive-fee
Disaggregation of Revenue [Line Items]
Revenues	167	99
Health | Firm-fixed-price
Disaggregation of Revenue [Line Items]
Revenues	417	392
Health | Time-and-materials and fixed-price-level-of-effort
Disaggregation of Revenue [Line Items]
Revenues	66	100
Health | DoD and U.S. Intelligence Community
Disaggregation of Revenue [Line Items]
Revenues	238	158
Health | Other government agencies
Disaggregation of Revenue [Line Items]
Revenues	385	407
Health | Commercial and non-U.S. customers
Disaggregation of Revenue [Line Items]
Revenues	$ 27	$ 26

Revenues from Contracts with _5

Revenues from Contracts with Customers (Contract Asset and Liabilities) (Details) - USD ($) $ in Millions	Apr. 01, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Contract assets - current:	$ 1,078	$ 1,022
Contract liabilities - current:	382	364
Contract liabilities - non-current:	$ 25	$ 24

Acquisitions, Divestitures, G_3

Acquisitions, Divestitures, Goodwill and Intangible Assets (Narrative) (Details) - USD ($)	Sep. 21, 2021	May 07, 2021	Apr. 01, 2022	Apr. 02, 2021	Apr. 29, 2022	Dec. 31, 2021	Jan. 01, 2021
Restructuring Cost and Reserve [Line Items]
Goodwill			$ 6,742,000,000			$ 6,744,000,000	$ 6,313,000,000
Goodwill impairments			0	$ 0
Amortization expense			59,000,000	$ 55,000,000
Civil
Restructuring Cost and Reserve [Line Items]
Goodwill			2,090,000,000			$ 2,097,000,000	$ 2,047,000,000
Reporting unit, percentage of fair value in excess of carrying amount						6.00%
Subsequent Event | Disposal Group, Held-for-sale, Not Discontinued Operations | Aviation & Missile Solutions LLC
Restructuring Cost and Reserve [Line Items]
Sale price of business disposal					$ 15,000,000
Gibbs & Cox
Restructuring Cost and Reserve [Line Items]
Preliminary purchase consideration		$ 375,000,000
Cash acquired		$ 1,000,000
Goodwill			276,000,000
Revenue			$ 27,000,000
Series of Individually Immaterial Business Acquisitions
Restructuring Cost and Reserve [Line Items]
Preliminary purchase consideration	$ 36,000,000
Goodwill	25,000,000
Intangible assets	$ 8,000,000

Acquisitions, Divestitures, G_4

Acquisitions, Divestitures, Goodwill and Intangible Assets (Schedule of intangible assets acquired) (Details) - Gibbs & Cox - Programs $ in Millions	May 07, 2021USD ($)
Acquired Indefinite-lived Intangible Assets [Line Items]
Weighted average amortization period	12 years
Finite-lived intangible assets	$ 89

Acquisitions, Divestitures, G_5

Acquisitions, Divestitures, Goodwill and Intangible Assets (Schedule of Changes in Goodwill by Segment) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Apr. 01, 2022	Dec. 31, 2021
Goodwill [Roll Forward]
Goodwill, Beginning Balance	$ 6,744	$ 6,313
Acquisitions of businesses	1	430
Divestiture of a business	(4)	(1)
Goodwill re-allocation		0
Foreign currency translation adjustments	1	2
Ending balance, Goodwill	6,742	6,744
Defense Solutions
Goodwill [Roll Forward]
Goodwill, Beginning Balance	3,681	3,300
Acquisitions of businesses	1	425
Divestiture of a business	(4)	(1)
Goodwill re-allocation		(17)
Foreign currency translation adjustments	8	(26)
Ending balance, Goodwill	3,686	3,681
Civil
Goodwill [Roll Forward]
Goodwill, Beginning Balance	2,097	2,047
Acquisitions of businesses	0	5
Divestiture of a business	0	0
Goodwill re-allocation		17
Foreign currency translation adjustments	(7)	28
Ending balance, Goodwill	2,090	2,097
Health
Goodwill [Roll Forward]
Goodwill, Beginning Balance	966	966
Acquisitions of businesses	0	0
Divestiture of a business	0	0
Goodwill re-allocation		0
Foreign currency translation adjustments	0	0
Ending balance, Goodwill	$ 966	$ 966

Acquisitions, Divestitures, G_6

Acquisitions, Divestitures, Goodwill and Intangible Assets (Schedule of intangible assets) (Details) - USD ($) $ in Millions	Apr. 01, 2022	Dec. 31, 2021
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying value	$ 2,029	$ 2,088
Finite-lived intangible assets, accumulated amortization	(1,016)	(1,007)
Finite-lived intangible assets, net carrying value	1,013	1,081
Indefinite-lived intangible assets	96	96
Total intangible assets, gross carrying value	2,125	2,184
Total intangible assets, net carrying value	1,109	1,177
In-process research and development
Acquired Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	92	92
Trade names
Acquired Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	4	4
Programs
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying value	1,701	1,722
Finite-lived intangible assets, accumulated amortization	(866)	(830)
Finite-lived intangible assets, net carrying value	835	892
Software and technology
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying value	230	230
Finite-lived intangible assets, accumulated amortization	(127)	(121)
Finite-lived intangible assets, net carrying value	103	109
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying value	91	97
Finite-lived intangible assets, accumulated amortization	(16)	(18)
Finite-lived intangible assets, net carrying value	75	79
Backlog
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying value	6	38
Finite-lived intangible assets, accumulated amortization	(6)	(37)
Finite-lived intangible assets, net carrying value	0	1
Trade names
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying value	1	1
Finite-lived intangible assets, accumulated amortization	(1)	(1)
Finite-lived intangible assets, net carrying value	$ 0	$ 0

Acquisitions, Divestitures, G_7

Acquisitions, Divestitures, Goodwill and Intangible Assets (Schedule of estimated annual amortization expense) (Details) - USD ($) $ in Millions	Apr. 01, 2022	Dec. 31, 2021
Estimated Annual Intangible Amortization Expense
2022 (remainder of year)	$ 173
2023	203
2024	150
2025	120
2026	96
2027 and thereafter	271
Finite-lived intangible assets, net carrying value	$ 1,013	$ 1,081

Fair Value Measurements (Financ

Fair Value Measurements (Financial Instruments Measured at Fair Value on Recurring Basis) (Details) - USD ($) $ in Millions	Apr. 01, 2022	Dec. 31, 2021
Carrying value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 13	$ 53
Fair value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 13	$ 53

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Billions	Apr. 01, 2022	Dec. 31, 2021
Fair value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt instrument	$ 5.1	$ 5.4
Carrying value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt instrument	5.1	$ 5.1
Designated as Hedging Instrument | Interest Rate Swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Hedged instrument, face amount	$ 1

Derivative Instruments (Interes

Derivative Instruments (Interest rate swaps) (Details) - USD ($) $ in Millions	Apr. 01, 2022	Dec. 31, 2021
Cash Flow Hedging | Interest Rate Swaps | Other long-term liabilities | Designated as Hedging Instrument
Derivative [Line Items]
Liability derivatives	$ 13	$ 53

Derivative Instruments (Narrati

Derivative Instruments (Narrative) (Details) $ in Millions	Apr. 01, 2022USD ($)
Derivative [Line Items]
Gains expected to be reclassified in the next 12 months	$ 15
Designated as Hedging Instrument | Interest Rate Swaps
Derivative [Line Items]
Hedged instrument, face amount	$ 1,000
Designated as Hedging Instrument | Interest Rate Swap, Maturity Date August 2025 | Unsecured Debt
Derivative [Line Items]
Stated interest rate (in percentage)	3.00%

Derivative Instruments (Effect

Derivative Instruments (Effect of Cash Flow Hedge) (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2022	Apr. 02, 2021
Derivatives, Fair Value [Line Items]
Total interest expense, net presented in the condensed consolidated statements of income in which the effects of cash flow hedges are recorded	$ 48	$ 45
Amount recognized in other comprehensive income	32	12
Interest Expense
Derivatives, Fair Value [Line Items]
Amount reclassified from accumulated other comprehensive income (loss) to interest expense, net	$ 6	$ 5

Debt (Summary of debt) (Details

Debt (Summary of debt) (Details) - USD ($)	Apr. 01, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Commercial Paper	$ 75,000,000	$ 0
Total short-term debt	455,000,000	380,000,000
Total long-term debt	4,670,000,000	4,696,000,000
Less current portion	(101,000,000)	(103,000,000)
Total long-term debt, net of current portion	4,569,000,000	4,593,000,000
Long-term debt	5,041,000,000	5,065,000,000
Unamortized debt discounts and deferred debt issuances costs	41,000,000	43,000,000
Unsecured Debt | $1,925 million term loan, due January 2025
Debt Instrument [Line Items]
Debt instrument, face amount	$ 1,925,000,000
Stated interest rate	1.84%
Effective interest rate	2.11%
Senior unsecured debt	$ 1,275,000,000	1,298,000,000
Unsecured Debt | $500 million notes, due May 2023
Debt Instrument [Line Items]
Debt instrument, face amount	$ 500,000,000
Stated interest rate	2.95%
Effective interest rate	3.17%
Senior unsecured debt	$ 499,000,000	498,000,000
Unsecured Debt | $500 million notes, due May 2025
Debt Instrument [Line Items]
Debt instrument, face amount	$ 500,000,000
Stated interest rate	3.63%
Effective interest rate	3.76%
Senior unsecured debt	$ 497,000,000	497,000,000
Unsecured Debt | $750 million notes due May 2030
Debt Instrument [Line Items]
Debt instrument, face amount	$ 750,000,000
Stated interest rate	4.38%
Effective interest rate	4.50%
Senior unsecured debt	$ 738,000,000	738,000,000
Unsecured Debt | $1,000 million notes, due February 2031
Debt Instrument [Line Items]
Debt instrument, face amount	$ 1,000,000,000
Stated interest rate	2.30%
Effective interest rate	2.38%
Senior unsecured debt	$ 990,000,000	990,000,000
Unsecured Debt | $250 million notes, due July 2032
Debt Instrument [Line Items]
Debt instrument, face amount	$ 250,000,000
Stated interest rate	7.13%
Effective interest rate	7.43%
Senior unsecured debt	$ 247,000,000	247,000,000
Unsecured Debt | $300 million notes, due July 2033
Debt Instrument [Line Items]
Debt instrument, face amount	$ 300,000,000
Stated interest rate	5.50%
Effective interest rate	5.88%
Senior unsecured debt	$ 158,000,000	158,000,000
Unsecured Debt | $300 million notes, due December 2040
Debt Instrument [Line Items]
Debt instrument, face amount	$ 300,000,000
Stated interest rate	5.95%
Effective interest rate	6.03%
Senior unsecured debt	$ 216,000,000	216,000,000
Unsecured Debt | Notes payable and finance leases due on various dates through fiscal 2032
Debt Instrument [Line Items]
Notes payable and finance leases due on various dates through fiscal 2032	$ 50,000,000	54,000,000
Unsecured Debt | Notes payable and finance leases due on various dates through fiscal 2032 | Minimum
Debt Instrument [Line Items]
Stated interest rate	1.56%
Unsecured Debt | Notes payable and finance leases due on various dates through fiscal 2032 | Maximum
Debt Instrument [Line Items]
Stated interest rate	4.18%
Unsecured Debt | Minimum
Debt Instrument [Line Items]
Stated interest rate	0.52%
Unsecured Debt | Maximum
Debt Instrument [Line Items]
Stated interest rate	1.13%
Unsecured Debt | $380 million term loan, due May 2022
Debt Instrument [Line Items]
Debt instrument, face amount	$ 380,000,000
Stated interest rate	1.59%
Effective interest rate	1.69%
Senior unsecured debt	$ 380,000,000	$ 380,000,000

Debt (Narrative) (Details)

Debt (Narrative) (Details)	May 07, 2021USD ($)	Apr. 01, 2022USD ($)increaseextension	Apr. 02, 2021USD ($)	Dec. 31, 2021USD ($)
Debt Instrument [Line Items]
Commercial paper outstanding		$ 75,000,000		$ 0
Payments of long-term debt		27,000,000	$ 26,000,000
Amortization of debt discount and debt issuance costs		$ 3,000,000	2,000,000
Commercial Paper
Debt Instrument [Line Items]
Debt instrument term		397 days
Commercial paper		$ 750,000,000
Minimum denominations of commercial paper		250,000
Unsecured Debt
Debt Instrument [Line Items]
Repayment of debt principal		24,000,000	24,000,000
Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term line of credit		$ 0		$ 0
Term Loan | Unsecured Debt
Debt Instrument [Line Items]
Debt instrument, face amount	$ 380,000,000
Debt instrument term	364 days
The Credit Agreement
Debt Instrument [Line Items]
Number of additional extensions | extension		2
Debt instrument, extension term (in years)		1 year
Covenant, adjusted consolidated total debt to consolidated EBITDA ratio		3.75
Number of potential leverage ratio increases | increase		2
Covenant, leverage ratio, maximum, potential increase following material acquisition		4.50
Covenant, consolidated EBITDA to interest expense ratio		3.50
The Credit Agreement | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Variable rate percentage		1.38%
The Credit Agreement | London Interbank Offered Rate (LIBOR) | Minimum
Debt Instrument [Line Items]
Variable rate percentage		1.13%
The Credit Agreement | London Interbank Offered Rate (LIBOR) | Maximum
Debt Instrument [Line Items]
Variable rate percentage		1.75%
The Credit Agreement | Unsecured Debt | Term Loan
Debt Instrument [Line Items]
Debt instrument, face amount		$ 1,900,000,000
The Credit Agreement | Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Unsecured borrowing capacity		750,000,000
Debt Payments, Excluding Refinanced Debt
Debt Instrument [Line Items]
Payments of long-term debt		$ 27,000,000	$ 26,000,000
2021 Credit Agreement
Debt Instrument [Line Items]
Covenant, adjusted consolidated total debt to consolidated EBITDA ratio		3.75
Covenant, leverage ratio, maximum, potential increase following material acquisition		4.50
Covenant, consolidated EBITDA to interest expense ratio		3.50
2021 Credit Agreement | Unsecured Debt | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Variable rate percentage	1.13%
2021 Credit Agreement | Unsecured Debt | Base Rate
Debt Instrument [Line Items]
Variable rate percentage	0.13%

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Apr. 01, 2022	Dec. 31, 2021
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	$ 4,344	$ 3,871
Ending Balance	4,008	4,344
Accumulated other comprehensive income
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(12)	(46)
Other comprehensive income (loss)	31	32
Taxes	(5)	(17)
Reclassification from accumulated other comprehensive income (loss)	6	19
Ending Balance	20	(12)
Foreign currency translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	22	30
Other comprehensive income (loss)	(2)	(3)
Taxes	4	(5)
Reclassification from accumulated other comprehensive income (loss)	0	0
Ending Balance	24	22
Unrecognized gain (loss) on derivative instruments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(41)	(70)
Other comprehensive income (loss)	32	18
Taxes	(9)	(8)
Reclassification from accumulated other comprehensive income (loss)	6	19
Ending Balance	(12)	(41)
Pension adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	7	(6)
Other comprehensive income (loss)	1	17
Taxes	0	(4)
Reclassification from accumulated other comprehensive income (loss)	0	0
Ending Balance	$ 8	$ 7

Earnings Per Share (Reconciliat

Earnings Per Share (Reconciliation of weighted average number of shares outstanding) (Details) - shares shares in Millions	3 Months Ended
	Apr. 01, 2022	Apr. 02, 2021
Earnings Per Share [Abstract]
Basic weighted average number of shares outstanding (in shares)	139	142
Dilutive common share equivalents-stock options and other stock awards (in shares)	1	2
Diluted weighted average number of shares outstanding (shares)	140	144

Earnings Per Share (Narrative)

Earnings Per Share (Narrative) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	Feb. 16, 2022	Apr. 01, 2022	Apr. 02, 2021
Equity, Class of Treasury Stock [Line Items]
Anti-dilutive shares (in shares)		1	1
Accelerated Share Repurchase
Equity, Class of Treasury Stock [Line Items]
Payments for repurchase of common stock	$ 500
Number of shares repurchased and retired (in shares)	4.5
Accelerated share repurchases, initial price paid per share (dollars per share)	$ 88.72

Sale of Accounts Receivable (Na

Sale of Accounts Receivable (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2022	Apr. 02, 2021
Receivables [Abstract]
Receivable collectible period	30 days
Sales of accounts receivable	$ 209	$ 465
Proceeds from sale of receivables	$ 209	$ 464

Sale of Accounts Receivable (Ac

Sale of Accounts Receivable (Accounts Receivable Sale Activity) (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2022	Apr. 02, 2021
Receivables [Abstract]
Sales of accounts receivable	$ 209	$ 465
Cash collections on sold receivables remitted to financial institution	(209)	(371)
Outstanding balance sold to financial institution	0	94
Cash collected but not yet remitted to financial institution	0	(19)
Sold receivables due from customers	$ 0	$ 75

Business Segments (Schedule of

Business Segments (Schedule of segment reporting information by segment) (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2022	Apr. 02, 2021
Segment Reporting Information [Line Items]
Revenues	$ 3,494	$ 3,315
Operating income (loss)	271	308
Corporate
Segment Reporting Information [Line Items]
Operating income (loss)	(23)	(20)
Defense Solutions
Segment Reporting Information [Line Items]
Revenues	2,049	1,958
Defense Solutions | Operating Segments
Segment Reporting Information [Line Items]
Operating income (loss)	133	152
Civil
Segment Reporting Information [Line Items]
Revenues	795	766
Civil | Operating Segments
Segment Reporting Information [Line Items]
Operating income (loss)	43	74
Health
Segment Reporting Information [Line Items]
Revenues	650	591
Health | Operating Segments
Segment Reporting Information [Line Items]
Operating income (loss)	$ 118	$ 102

Commitments and Contingencies (

Commitments and Contingencies (Narrative) (Details)	Oct. 30, 2020USD ($)	Nov. 22, 2019patent	Aug. 30, 2018USD ($)	Apr. 10, 2018USD ($)	Jan. 31, 2021USD ($)	Apr. 01, 2022USD ($)
Standby Letters of Credit
Legal Proceedings [Line Items]
Amount outstanding						$ 51,000,000
Performance Guarantee
Legal Proceedings [Line Items]
Surety bonds notional amount						$ 100,000,000
Virnet X Inc
Legal Proceedings [Line Items]
Amount awarded from other party	$ 503,000,000		$ 595,000,000	$ 502,000,000
Royalty rate awarded (per device)	$ 0.84		1.20
Awarded to the other party, interest and legal fees			$ 93,000,000
Number of infringed patents | patent		2
Number of infringed other patents | patent		2
Additional costs and interest					$ 75,000,000
Leidos
Legal Proceedings [Line Items]
Litigation settlement, percentage of total (percentage)					25.00%

Commitments and Contingencies_2

Commitments and Contingencies (Future Expirations Maturity Table) (Details) - Standby Letters of Credit and Surety Bonds $ in Millions	Apr. 01, 2022USD ($)
Guaranteed Obligation, Type [Line Items]
2022 (remainder of year)	$ 38
2023	11
2024	81
2025	5
2026	2
2027 and thereafter	14
Guaranteed obligation	$ 151